Roopa Kanakatti Shankar

Roopa Kanakatti Shankar

Auto-generated profile, based on publicly available information

Roopa Kanakatti Shankar

Division of Endocrinology, Children's National Hospital , Washington, DC 20010

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2024 in European Journal of Endocrinology
Verified
Journal Article
Open access
PDF file
CGClaus H Gravholt
Claus H Gravholt
NANiels H Andersen
Niels H Andersen
SCSophie Christin-Maitre
Sophie Christin-Maitre
SDShanlee M Davis
Shanlee M Davis
ADAnthonie Duijnhouwer
Anthonie Duijnhouwer
PBPhilippe F Backeljauw
Philippe F Backeljauw
Turner syndrome (TS) affects 50 per 100 000 females. TS affects multiple organs through all stages of life, necessitating multidisciplinary care. This guideline extends previous ones and includes important new advances, within diagnostics and genetics, estrogen treatment, fertility, co-morbidities, and neurocognition and neuropsychology. Exploratory meetings were held in 2021 in Europe and United States culminating with a consensus meeting in Aarhus, Denmark in June 2023. Prior to this, eight groups addressed important areas in TS care: (1) diagnosis and genetics, (2) growth, (3) puberty and estrogen treatment, (4) cardiovascular health, (5) transition, (6) fertility assessment, monitoring, and counselling, (7) health surveillance for comorbidities throughout the lifespan, and (8) neurocognition and its implications for mental health and well-being. Each group produced proposals for the present guidelines, which were meticulously discussed by the entire group. Four pertinent questions were submitted for formal GRADE (Grading of Recommendations, Assessment, Development and Evaluation) evaluation with systematic review of the literature. The guidelines project was initiated by the European Society for Endocrinology and the Pediatric Endocrine Society, in collaboration with members from the European Society for Pediatric Endocrinology, the European Society of Human Reproduction and Embryology, the European Reference Network on Rare Endocrine Conditions, the Society for Endocrinology, and the European Society of Cardiology, Japanese Society for Pediatric Endocrinology, Australia and New Zealand Society for Pediatric Endocrinology and Diabetes, Latin American Society for Pediatric Endocrinology, Arab Society for Pediatric Endocrinology and Diabetes, and the Asia Pacific Pediatric Endocrine Society. Advocacy groups appointed representatives for pre-meeting discussions and the consensus meeting.

31 January 2014 in Current Topics in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
EOElizabeth A. Ottinger
Elizabeth A. Ottinger
MKMark L. Kao
Mark L. Kao
NCNuria Carrillo-Carrasco
Nuria Carrillo-Carrasco
NYNicole Yanjanin
Nicole Yanjanin
RSRoopa Kanakatti Shankar
Roopa Kanakatti Shankar
JMJohn C. McKew
John C. McKew
In 2010, the National Institutes of Health (NIH) established the Therapeutics for Rare and Neglected Diseases (TRND) program within the National Center for Advancing Translational Sciences (NCATS), which was created to stimulate drug discovery and development for rare and neglected tropical diseases through a collaborative model between the NIH, academic scientists, nonprofit organizations, and pharmaceutical and biotechnology companies. This paper describes one of the first TRND programs, the development of 2-hydroxypropyl-β-cyclodextrin (HP-β-CD) for the treatment of Niemann-Pick disease type C1 (NPC1). NPC is a neurodegenerative, autosomal recessive rare disease caused by a mutation in either the NPC1 (about 95% of cases) or the NPC2 gene (about 5% of cases). These mutations affect the intracellular trafficking of cholesterol and other lipids, which leads to a progressive accumulation of unesterified cholesterol and glycosphingolipids in the CNS and visceral organs. Affected individuals typically exhibit ataxia, swallowing problems, seizures, and progressive impairment of motor and intellectual function in early childhood, and usually die in adolescence. There is no disease modifying therapy currently approved for NPC1 in the US. A collaborative drug development program has been established between TRND, public and private partners that has completed the pre-clinical development of HP-β-CD through IND filing for the current Phase I clinical trial that is underway. Here we discuss how this collaborative effort helped to overcome scientific, clinical and financial challenges facing the development of new drug treatments for rare and neglected diseases, and how it will incentivize the commercialization of HP-β-CD for the benefit of the NPC patient community.

18 December 2017 in Therapeutic Advances in Endocrinology and Metabolism
Verified
Journal Article
Open access
RSRoopa Kanakatti Shankar
Roopa Kanakatti Shankar
PBPhilippe F. Backeljauw
Philippe F. Backeljauw
Turner syndrome (TS) is characterized by partial or complete loss of the second X-chromosome in phenotypic females resulting in a constellation of clinical findings that may include lymphedema, cardiac anomalies, short stature, primary ovarian failure and neurocognitive difficulties. Optimizing health care delivery is important to enable these individuals achieve their full potential. We review the current best practice management recommendations for individuals with TS focusing on the latest consensus opinion in regard to genetic diagnosis, treatment of short stature, estrogen supplementation, addressing psychosocial issues, as well screening for other comorbidities. A multidisciplinary approach and a well-planned transition to adult follow-up care will improve health care delivery significantly for this population.

1 March 2015 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
APAnna Petryk
Anna Petryk
RSRoopa Kanakatti Shankar
Roopa Kanakatti Shankar
NGNeelam Giri
Neelam Giri
AHAnthony N. Hollenberg
Anthony N. Hollenberg
MRMeilan M. Rutter
Meilan M. Rutter
SRSusan Rose
Susan Rose
Context: Endocrine problems are common in patients with Fanconi anemia (FA). About 80% of children and adults with FA have at least one endocrine abnormality, including short stature, GH deficiency, abnormal glucose or insulin metabolism, dyslipidemia, hypothyroidism, pubertal delay, hypogonadism, or impaired fertility. The goal of this report is to provide an overview of endocrine abnormalities and guidelines for routine screening and treatment to allow early diagnosis and timely intervention. Evidence Acquisition: This work is based on a comprehensive literature review, including relevant articles published between 1971 and 2014, and proceedings of a Consensus Conference held by the Fanconi Anemia Research Fund in 2013. Evidence Synthesis: The panel of experts collected published evidence and discussed its relevance to reflect current information about the endocrine care of children and adults with FA before the Consensus Conference and through subsequent deliberations that led to the consensus. Conclusions: Individuals with FA should be routinely screened for endocrine abnormalities, including evaluation of growth; glucose, insulin, and lipid metabolism; thyroid function; puberty; gonadal function; and bone mineral metabolism. Inclusion of an endocrinologist as part of the multidisciplinary patient care team is key to providing comprehensive care for patients with FA.

21 December 2016 in Journal of Biomedical Materials Research Part A
Verified
Journal Article
Closed access
PDF file
MLMichael G. Lancina
Michael G. Lancina
RSRoopa Kanakatti Shankar
Roopa Kanakatti Shankar
HYHu Yang
Hu Yang

10 October 2012 in Pediatric Diabetes
Verified
Journal Article
Closed access
PDF file
RSRoopa Kanakatti Shankar
Roopa Kanakatti Shankar
CPCatherine Pihoker
Catherine Pihoker
LDLawrence M. Dolan
Lawrence M. Dolan
DSDebra Standiford
Debra Standiford
ABAngela Badaru
Angela Badaru
FGfor the SEARCH for Diabetes in Youth Study Group
for the SEARCH for Diabetes in Youth Study Group